Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.49 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 2/20 | 0.44 |
| ▸ | CDK8 | P49336 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAK | O14976 | 1/20 | 0.42 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | STK16 | O75716 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.42 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1195881 | 0.84 | ALK (0.50) | SLC22A12NCF1CCNCCDK8HTT | |
| SCHEMBL14690611 | 0.83 | SLC22A12 (0.51) | SLC22A12NCF1CHEK1PIM1AKT1 | |
| SCHEMBL29896761 | 0.83 | SLC22A12 (0.51) | SLC22A12NCF1CHEK1PIM1AKT1 | |
| SCHEMBL17059461 | 0.79 | PARP1 (0.47) | NCF1CCNCCDK8HTTALDH1A1 | |
| SCHEMBL359558 | 0.76 | NT5E (0.50) | SLC22A12NCF1CHEK1PIM1AKT1 | |
| SCHEMBL16705385 | 0.76 | CDK8 (0.49) | SLC22A12CCNCCDK8GAKRIPK2 | |
| SCHEMBL8123511 | 0.76 | KDM4E (0.37) | NCF1CCNCCDK8HTTALDH1A1 | |
| SCHEMBL18544878 | 0.76 | HTR1A (0.54) | SLC22A12HTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL16247955 | 0.76 | SLC22A12 (0.49) | SLC22A12NCF1CHEK1PIM1AKT1 | |
| SCHEMBL360254 | 0.76 | SLC22A12 (0.51) | SLC22A12NCF1CHEK1PIM1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168118-A1 | N-(5-QUINOLIN-6-YL)PYRIDIN-3-YL) BENZSULFAMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USE THEREOF | SECOND MILITARY MEDICAL UNIVERSITY, PLA (CN) | 2016-06-16 | — | — | US | claimed |
| EP-2915810-A1 | N-(5-(QUINOLIN-6-YL)PYRIDIN-3-YL) BENZSULFAMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USE THEREOF | The Second Military Medical University, PLA (CN) | 2015-09-09 | — | — | EP | claimed |
| WO-2025049976-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240165279-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP) TARGETED IMAGING AND THERAPY IN FIBROSIS | PURDUE RESEARCH FOUNDATION | 2024-05-23 | — | — | US | disclosed |
| US-11890357-B2 | Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis | PURDUE RESEARCH FOUNDATION (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230158153-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2023-05-25 | — | — | US | disclosed |
| US-20230158153-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2023-05-25 | — | — | US | disclosed |
| US-20230158153-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2023-05-25 | — | — | US | disclosed |
| EP-4132921-A2 | PI3 KINASE INHIBITORS AND USES THEREOF | Purdue Research Foundation (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20230033291-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP) TARGETED IMAGING AND THERAPY IN FIBROSIS | PURDUE RESEARCH FOUNDATION | 2023-02-02 | — | — | US | disclosed |
| US-11426472-B2 | Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis | PURDUE RESEARCH FOUNDATION (US) | 2022-08-30 | — | — | US | disclosed |
| US-20100152112-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2010-06-17 | — | — | US | disclosed |
| EP-2192902-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20080300239-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300239-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300239-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| WO-2008144464-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144464-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144463-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144463-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11890357-B2 | Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis | FAP, FIBP, MMP1 | SLC22A12 3390/4885NCF1 1267/4885CHEK1 4395/4885 |
| US-20100152112-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | JAK3, PI4KA, PIP4K2A | SLC22A12 3836/4885NCF1 1248/4885CHEK1 219/4885 |
| US-20240165279-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP) TARGETED IMAGING AND THERAPY IN FIBROSIS | FAP, FIBP, MMP1 | SLC22A12 3368/4885NCF1 1228/4885CHEK1 4421/4885 |
| US-20230158153-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | MMP1, PIK3CA, AKT2 | SLC22A12 3619/4885NCF1 854/4885CHEK1 693/4885 |
| US-20230033291-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP) TARGETED IMAGING AND THERAPY IN FIBROSIS | FAP, FIBP, MMP1 | SLC22A12 3417/4885NCF1 1254/4885CHEK1 4382/4885 |
| US-20160168118-A1 | N-(5-QUINOLIN-6-YL)PYRIDIN-3-YL) BENZSULFAMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USE THEREOF | GLS2, CYP3A5, HCCS | SLC22A12 3126/4885NCF1 3795/4885CHEK1 1249/4885 |
| US-20080300239-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CG, PIK3CB | SLC22A12 3927/4885NCF1 1224/4885CHEK1 373/4885 |
| US-11426472-B2 | Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis | FAP, FIBP, MMP1 | SLC22A12 3390/4885NCF1 1267/4885CHEK1 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.